Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Top Cited Papers
- 1 February 2013
- journal article
- review article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 12 (2), 207-216
- https://doi.org/10.1016/s1474-4422(12)70291-0
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AG11378)
This publication has 114 references indexed in Scilit:
- Cognition, reserve, and amyloid deposition in normal agingAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- Aβ amyloid and glucose metabolism in three variants of primary progressive aphasiaAnnals of Neurology, 2008
- Effect of infarcts on dementia in the Baltimore longitudinal study of agingAnnals of Neurology, 2008
- β‐amyloid burden is not associated with rates of brain atrophyAnnals of Neurology, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004